PRMT1作为多发性骨髓瘤中关键生存依赖标的治疗潜力
bioRxiv : the preprint server for biology
|February 20, 2025
概括
多发性髓瘤细胞依赖蛋白质氨酸N-甲基转移酶1 (PRMT1) 才能生存. 用GSK3368715抑制PRMT1可降低细胞增殖和DNA损伤反应,为这种血液性恶性瘤提供潜在的新疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 多发性骨髓瘤 (MM) 是一种流行的血液性恶性瘤,由于药物耐药性和复发,在治疗中存在重大挑战.
- 确定新的治疗点对于改善MM治疗结果至关重要.
- 蛋白质氨酸N-甲基转移酶1 (PRMT1) 已与包括MM在内的各种癌症有关,并与化学抵抗有关.
研究的目的:
- 研究PRMT1作为多发性骨髓瘤潜在治疗点的作用.
- 为了评估PRMT1抑制在MM细胞中的有效性.
主要方法:
- 一个定制的CRISPR/Cas9屏幕针对DNA损伤反应基因.
- 用PRMT1抑制剂GSK3368715.15治疗MM细胞系的方法
- 分析阿金甲基化水平 (ADMA,MMA).
- 细胞周期分析.
- 基因表达分析.
- 反相蛋白质阵列 (RPPA) 分析.
主要成果:
- PRMT1被确定为MM细胞的关键生存依赖性.
- 治疗GSK3368715以剂量依赖的方式降低了MM细胞存活率.
- 抑制PRMT1改变了氨酸甲基化模式,并诱导了G0/G1细胞周期停止.
- 抑制PRMT1降低了参与细胞增殖,DNA复制和DNA损伤反应 (DDR) 的基因.
- RPPA证实了细胞循环调节和DDR通路中的蛋白质水平降低.
结论:
- 毫米细胞对PRMT1的生存非常依赖.
- 抑制PRMT1代表了对多发性骨髓瘤的有前途的治疗策略.
- 向PRMT1可能会克服化学抵抗并提高MM的治疗疗效.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K


